Page 2501 - Williams Hematology ( PDFDrive )

2472 Index Index 2473

Next-generation sequencing (NGS) etiology and pathogenesis, 1122f, 1129 Nitrosoureas, 319t, 329, 330, 1824
for chromatin accessibility studies, history and classification, 1128–1129 Nitrous oxide, 604–605, 801
161–162 laboratory features and differential Nitrovasodilators, 1968t
for chromatin modification studies, 161 diagnosis, 1130 Nix, 487
as clinical tool, 162 pathology and clinical manifestations, NK. See under Natural killer (NK)
data analysis methods, 160–161 1129–1130, 1129f NKG2A, 1190, 1192
for DNA methylation and treatment, 1130 NLRs (nucleotide-binding oligomerization
hydroxymethylation studies, 162 types, 1129 domain-like receptors), 298–299,
overview, 152, 155–156 Night sweats, history of, 4 299f, 1008, 1063, 1065f
by pH change sensing, 157–158, 157f Nijmegen breakage syndrome, 530t, 1227, NO. See Nitric oxide (NO)
for research purposes, 162 1575t Nocardia infection, 369, 383. See also
Sanger, 155 acute lymphoblastic leukemia and, 1507 Bacterial infections
single-molecule, 158–159, 158f Nilotinib Nocturnal enuresis, 770–771
by synthesis, 156–157, 156f adverse effects, 339t, 341, 1451t, 1454 Nodal marginal zone lymphoma, 1495t, 1592,
targeted, 159–160, 159f for chronic myelogenous leukemia, 176, 1592f, 1667–1668, 1668f
for transcriptome analysis, 161 339t, 1451t, 1454, 1457, 1466 NOD (nucleotide-binding oligomerization
NF1, 1444, 1471 comparison with other tyrosine kinase domain)-like receptors (NLRs),
NFATs (nuclear factor of activated T cells), inhibitors, 1451t, 1454 298–299, 299f, 1008
1178, 1528 drug interactions, 339t, 1451t NOD (nucleotide-binding oligomerization
NFE-2, 730 pharmacology, 339t, 340–341 domain) pathways, 299–300, 301f
NF-E2, 893, 894, 1818, 1820 Nippostrongylus, 956 Nodular lymphocyte-predominant Hodgkin
NFKBIE, 231t Nippostrongylus brasiliensis, 956 lymphoma (NLPHL). See Hodgkin
NF-κB (nuclear factor-kappa B) Nitric oxide (NO), 1970–1971 lymphoma, nodular lymphocyte-
apoptosis regulation and, 208f, 209 characteristics, 1967 predominant
in chronic lymphocytic leukemia, 1528 in disseminated intravascular coagulation, Non-Burkitt (small noncleaved cell)
in extranodal marginal zone lymphoma of 2203 lymphoma, 187
MALT type, 1663–1664 functions, 1970–1971 Nongerminal center B-cell–like lymphoma,
impaired activation, 1220 in high-altitude dwellers, 875 1496t
in inflammation, 2202 in inflammatory response, 280, 286–287, Non-Hodgkin lymphoma. See Lymphomas
in myeloma, 1710, 1711 286t Nonhomologous DNA end joining (NHEJ),
p210 BCR-ABL and, 1444 inhaled, 797 1166, 1169
in splenic marginal zone lymphoma, 1666 pathophysiology, 797 Nonhomologous end-joining (NHEJ), 453
in toll-like receptor signaling, 1054, 1055f platelet adhesion and, 1834, 1885 Nonimmune hydrops, 849
in Waldenström macroglobulinemia, platelet aggregation and, 1971 Nonimmunologic protein adsorption,
1786–1787 platelet function and, 2077, 2078 drug-induced, 825f, 826t, 830t, 831
NF-κB essential modulator (NEMO), 298, red blood cells and, 796–797, 796f, 797f Nonopsonic receptors, 1054–1055, 1057t
1215 scavenging, in sickle cell disease, 764 Nonsense-mediated RNA decay, 733
NF-κB inhibitors, for acute myelogenous synthesis, 1885, 1971 Nonsense mutations, 146
leukemia, 1403 Nitric oxide synthase (NOS) Non-ST elevation myocardial infarction
NF-κB pathway, 233t, 1606 endothelial activation and, 1970–1971 (NSTEMI), 2296. See also
NGAL (neutrophil gelatinase-associated in inflammatory response, 286–287 Myocardial infarction (MI)
lipocalin), 1009, 1012t, 1013–1014 platelet effects, 1971 Nonsteroidal antiinflammatory agents.
NGS. See Next-generation sequencing (NGS) structure and biochemical properties, 1971 See NSAIDs
NHEJ (nonhomologous DNA end joining), vascular tone and, 2283, 2283f Non–toll-like, nonopsonic receptors,
1166, 1169 Nitrites, toxic methemoglobinemia, 789, 790t 1054–1055, 1057t
NHEJ (nonhomologous end-joining), 453 Nitroblue tetrazolium (NBT), in newborn, Nontropical sprue, 597
Niacin deficiency (pellagra), 652 107 NOP10, 531f
Niclosamide, 604 Nitrofurantoin NOP10, 531
Nicotinamide, 1193 maternal ingestion of, effect on fetus and Normocytic anemia, 506
Nicotinamide adenine dinucleotide. See newborn, 112, 112t NOS. See Nitric oxide synthase (NOS)
under NAD platelet function and, 2078 Notch, 1824
Nicotinamide phosphoribosyltransferase Nitrogen mustard, 329, 330, 1106, 1685, Notch 1, 1606
(NAMPT), 200 1687. See also MOPP regimen; NOTCH1/2
Niemann-Pick disease, 1128–1130 Stanford V regimen in chronic lymphocytic leukemia, 231t,
course and prognosis, 1130 Nitroglycerin, 790t, 2078, 2295 1529
epidemiology, 1129 Nitroprusside, 2078 in follicular lymphoma, 236t

Kaushansky_index_p2393-2506.indd 2472 9/21/15 3:22 PM